Malaria is a serious infectious disease caused by the Plasmodium parasite, with treatment goals aimed at rapidly eliminating the parasite, alleviating symptoms, and preventing complications and disease transmission. Modern medicine has developed various treatment strategies, and treatment plans should be individually adjusted based on factors such as the type of infection, patient age, severity of infection, and drug resistance. Timely diagnosis and treatment are key to reducing mortality, especially in severe cases, where immediate hospitalization and intensive treatment are required.
The principles of malaria treatment include "early intervention" and "stratified medication." In terms of drug selection, artemisinin-based combination therapy (ACT) has become the internationally recognized first-line treatment. Additionally, supportive therapy, environmental preventive measures, and patient health education are equally important. The treatment process requires close monitoring of parasite load and patient physiological indicators to ensure efficacy and avoid the spread of resistance.
Different species of Plasmodium exhibit significant differences in drug response. Infections caused by Plasmodium falciparum require immediate use of potent antimalarial drugs, as they may lead to life-threatening complications such as cerebral malaria. Plasmodium vivax requires the additional use of primaquine to eradicate dormant hypnozoites in the liver. Treatment plans should be adjusted based on the resistance map of the infection area; for example, cases of chloroquine resistance have emerged in Southeast Asia.
Patients with mild symptoms are usually treated with oral medications, while severe patients require immediate intravenous administration. The World Health Organization recommends that for suspected severe malaria patients, intravenous formulations of artemisinin derivatives (such as artesunate) should be initiated before diagnosis. Stratified treatment also includes subsequent oral consolidation therapy to ensure complete clearance of parasites from the body.
ACT is currently the most effective treatment combination, combining artemisinin-based drugs with other antimalarial medications to delay the development of resistance. Common combinations include artesunate with mefloquine or artesunate with amodiaquine. This therapy must be taken continuously for 3 to 7 days, effectively reducing parasite numbers and lowering the risk of severe disease.
Patients with high fever require antipyretics (such as acetaminophen) and electrolyte supplementation. Severe patients with respiratory failure or coma may require intubation and mechanical ventilation. Organ failure due to microvascular obstruction requires the use of vasopressors to maintain blood pressure, and monitoring of renal function and coagulation abnormalities.
Patients with cerebral malaria may experience seizures and altered consciousness, requiring benzodiazepines to control seizures. Patients with severe anemia may need blood transfusions, while those with renal dysfunction must have certain drug doses restricted. In resource-limited areas, supplementation with glucose and vitamins can improve metabolic disturbances.
During treatment, patients should use insecticide-treated mosquito nets and apply environmental sprays around their living areas. When going out, they should wear long-sleeved clothing and apply insect repellent containing DEET. Patients who have been infected with Plasmodium vivax, even after symptom relief, should have regular follow-ups to monitor for residual dormant hypnozoites in the liver.
Patients should be informed of the importance of completing the medication regimen, as discontinuing treatment can easily lead to resistance. Blood screening should be repeated 3 to 6 months after treatment to confirm complete clearance of the parasite. Travelers who have been to high-risk areas are advised to undergo follow-up checks within 3 months of symptom onset.
Researchers are developing single-dose antimalarial drugs, such as tafenoquine, which can treat and prevent relapses simultaneously. Gene editing technology is also being applied to develop inhibitors targeting parasite proteases to avoid resistance issues with existing drugs. New drug delivery methods, such as enteric-coated capsules or subcutaneous implantable drug delivery systems, can ensure stable release of medications within the body.
The RTS,S/AS01 vaccine received emergency use authorization from the World Health Organization in 2021, with four doses reducing the risk of severe disease. Research teams are developing mRNA vaccines targeting the intra-erythrocytic stage of the parasite and exploring the use of monoclonal antibodies to neutralize parasite surface antigens. Additionally, using artificial intelligence to analyze patient genomes to formulate personalized treatment plans is also a direction for personalized medicine development.
If experiencing a high fever exceeding 40°C, severe headache accompanied by altered consciousness, dark brown urine, or unexplained bleeding, immediate medical attention is required. Those who have traveled to malaria-endemic areas and develop symptoms within 3 weeks should undergo blood tests, even if symptoms are mild. Patients with chronic liver or kidney disease who become infected need to be evaluated by an infectious disease specialist for adjustments in drug metabolism. Pregnant women in late pregnancy who become infected should be referred to a specialized center for dual assessment of maternal and fetal safety.
If symptoms do not improve after treatment or if fever recurs within 14 days, blood tests should be re-evaluated along with drug sensitivity testing. Those who have had allergic reactions to antimalarial drugs should discuss alternative therapies with their physician. Patients infected in high-resistance risk areas are advised to undergo 6 months of follow-up after treatment to confirm cure.
If symptoms such as fever and chills completely resolve after treatment, and blood tests confirm the disappearance of the Plasmodium, this typically indicates successful treatment. Close observation is still recommended within 4 weeks after treatment; if fever recurs, immediate medical attention is necessary, as some cases may relapse due to residual parasites. Blood follow-up tests are advised after completing treatment to ensure complete clearance of the parasites.
Should daily diet or routine be adjusted during malaria treatment?During treatment, a light diet is recommended, avoiding alcohol to reduce liver metabolic burden. Taking antimalarial drugs may cause gastrointestinal discomfort, so they can be taken with small meals. Adequate rest helps the immune system recover, but excessive fatigue should be avoided, especially during fever, where rest should be prioritized.
After recovering from malaria, will there be drug resistance?Individual drug resistance to antimalarials does not arise from the person themselves, but rather the species of Plasmodium may possess inherent resistance. If relapse occurs after treatment, it is important to inform the physician of the previous medication history to adjust to different classes of drugs (such as artemisinin derivatives and partner drugs) to avoid treatment failure.
Is it safe to travel back to malaria-endemic areas shortly after recovering from malaria?If there has been no reinfection after recovery, there are no restrictions on traveling back to high-risk areas shortly after, but preventive measures against mosquitoes should be reapplied. It is advisable to consult a physician before departure, as prophylactic antimalarial medications (such as doxycycline or mefloquine) may be needed, along with physical protections like insect repellent and long-sleeved clothing.
Is it normal to experience dizziness or muscle pain after malaria treatment?Some antimalarial drugs (such as chloroquine) may cause dizziness, nausea, and other side effects, which usually resolve within a few days. If symptoms are severe or continue to worsen, medication should be stopped immediately and medical attention sought, as this may indicate drug allergy or intolerance. Muscle pain may also be a post-malaria sequela, and assessment with a physician is necessary to determine if additional supportive therapy is needed.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
